Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone
- 1 November 2001
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 111 (7) , 587
- https://doi.org/10.1016/s0002-9343(01)00927-5
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 casesThe American Journal of Medicine, 2001
- Serious adverse events experienced by patients with chronic heart failure taking spironolactoneHeart, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.The American Journal of Cardiology, 1996
- Consequences of fluid loss in patients treated with ACE inhibitorsPublished by Oxford University Press (OUP) ,1987